China National Accord Medicines Corp. Hits Day Low Amid Price Pressure at CNY 20.77

China National Accord Medicines Corp. experienced a notable decline today, with the stock dropping by 3.44% on July 17, 2026. The stock reached an intraday low of CNY 20.77, reflecting ongoing challenges in its performance metrics. Over the past year, the company has seen a return of -9.11%, significantly underperforming the China Shanghai Composite, which gained 7.03% during the same period. In terms of financial health, the company reported a low operating cash flow of CNY 620.2 million and an interest coverage ratio of 1,011.46, indicating potential liquidity concerns. The inventory turnover ratio stood at 7.9 times, the lowest in recent assessments. Despite these challenges, the stock maintains a relatively attractive valuation with a price-to-book ratio of 0.57 and a return on equity of 6.01%. The company has a market capitalization of CNY 10,704 million and offers a dividend yield of 1.66%. However, its long-term growth prospects appear limited, with net sales growing at an annual rate of just 3.02% over the last five years.